10x Genomics (TXG) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.14
- EPS estimate
- −$0.24
- EPS surprise
- +42.41%
- Revenue surprise
- +2.97%
- Revenue
- $151.0M
- Revenue estimate
- $146.7M
- Reported
- Aug 6, 2026
10x Genomics reported Q2 2026 results on August 6, 2026. It posted a loss of $0.14 per share, narrower than the expected $0.24 loss, a 42.41% beat. Revenue was $151.0 million, 2.97% above the $146.7 million estimate. A year earlier, in Q2 2025, the company earned $0.28 per share on revenue of $172.9 million, so revenue fell about 13% year over year.
That Q2 2025 profit is the only profitable quarter in the table; the other 19 were losses. Annual losses per share were $1.47 in 2022, $2.17 in 2023, $1.52 in 2024 and $0.35 in 2025. Annual revenue was $516.4 million in 2022, $618.7 million in 2023, $610.8 million in 2024 and $642.8 million in 2025. Quarterly revenue peaked at $184.0 million in Q4 2023. The company beat EPS estimates in each of the last four quarters and in 12 of the last 20.
10x Genomics reported Q3 results between October 29 and November 6 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether the loss stays within the $0.10 to $0.22 per share range of the last four quarters.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$0.24 | −$0.14 | +42.41% | $151.0M | SEC |
| Q1 2026 | May 7, 2026 | −$0.28 | −$0.10 | +63.65% | $150.8M | SEC |
| Q4 2025 | Feb 12, 2026 | −$0.20 | −$0.13 | +35.90% | $166.0M | SEC |
| Q3 2025 | Nov 6, 2025 | −$0.29 | −$0.22 | +23.72% | $149.0M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.37 | $0.28 | +175.72% | $172.9M | SEC |
| Q1 2025 | May 8, 2025 | −$0.47 | −$0.28 | +40.09% | $154.9M | SEC |
| Q4 2024 | Feb 12, 2025 | −$0.30 | −$0.40 | −33.65% | $165.0M | SEC |
| Q3 2024 | Oct 29, 2024 | −$0.33 | −$0.30 | +8.70% | $151.7M | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.48 | −$0.32 | +33.19% | $153.1M | SEC |
| Q1 2024 | Apr 30, 2024 | −$0.50 | −$0.50 | +0.06% | $141.0M | SEC |
| Q4 2023 | Feb 15, 2024 | −$0.35 | −$0.41 | −17.38% | $184.0M | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.46 | −$0.79 | −71.59% | $153.6M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.40 | −$0.53 | −32.67% | $146.8M | SEC |
| Q1 2023 | May 3, 2023 | −$0.37 | −$0.44 | −17.52% | $134.3M | SEC |
| Q4 2022 | Feb 15, 2023 | −$0.28 | −$0.15 | +45.75% | $156.2M | SEC |
| Q3 2022 | Nov 2, 2022 | −$0.47 | −$0.37 | +20.75% | $131.1M | SEC |
| Q2 2022 | Aug 8, 2022 | −$0.39 | −$0.57 | −46.98% | $114.6M | SEC |
| Q1 2022 | May 4, 2022 | −$0.34 | −$0.38 | −12.66% | $114.5M | SEC |
| Q4 2021 | Feb 16, 2022 | −$0.09 | −$0.16 | −85.40% | $143.5M | SEC |
| Q3 2021 | Nov 3, 2021 | −$0.19 | −$0.15 | +20.63% | $125.3M | SEC |
Quarterly revenue
Frequently asked questions
When did 10x Genomics (TXG) last report earnings?
10x Genomics last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did TXG beat earnings estimates?
Yes. 10x Genomics reported EPS of −$0.14 for Q2 2026 against a −$0.24 estimate — a 42.41% beat.
How much revenue did TXG report last quarter?
10x Genomics reported $151.0M in revenue for Q2 2026, against a consensus estimate of $146.7M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.